These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 17951903)
41. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194 [TBL] [Abstract][Full Text] [Related]
42. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109 [TBL] [Abstract][Full Text] [Related]
43. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Bahrami B; Hong T; Zhu M; Schlub TE; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195 [TBL] [Abstract][Full Text] [Related]
44. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Takamura Y; Kubo E; Akagi Y Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of the Effect of Intravitreal Bevacizumab (Avastin) in Patients with Diabetic Macular Edema. Pawan P; Joshi P; Pradhan E; Subedi P Nepal J Ophthalmol; 2020 Jul; 12(24):236-244. PubMed ID: 33978618 [TBL] [Abstract][Full Text] [Related]
46. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: a case report. Sharma A; Madhusudhan RJ; Nadahalli V; Damgude SA; Sundaramoorthy SK Indian J Ophthalmol; 2012; 60(3):234-5. PubMed ID: 22569393 [TBL] [Abstract][Full Text] [Related]
47. Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema. Ozkiriş A Doc Ophthalmol; 2010 Jun; 120(3):243-50. PubMed ID: 20140695 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274 [TBL] [Abstract][Full Text] [Related]
50. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Yanyali A; Aytug B; Horozoglu F; Nohutcu AF Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433 [TBL] [Abstract][Full Text] [Related]
51. Bevacizumab intravitreal injections in the treatment of diabetic macular oedema. Małgorzata W; Diana D; Agnieszka B; Zofia M Klin Oczna; 2013; 115(1):15-9. PubMed ID: 23882733 [TBL] [Abstract][Full Text] [Related]
52. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585 [TBL] [Abstract][Full Text] [Related]
53. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
54. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. Byeon SH; Kwon YA; Oh HS; Kim M; Kwon OW J Ocul Pharmacol Ther; 2007 Aug; 23(4):387-94. PubMed ID: 17803438 [TBL] [Abstract][Full Text] [Related]
55. Efficacy of intravitreal bevacizumab on diabetic macular oedema in an African population. Kyei S; Asare FA; Assan JK; Zaabaar E; Assiamah F; Obeng EO; Asiedu K Ir J Med Sci; 2023 Dec; 192(6):2777-2783. PubMed ID: 36988835 [TBL] [Abstract][Full Text] [Related]
56. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006 [TBL] [Abstract][Full Text] [Related]
58. Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema. Tsilimbaris MK; Pandeleondidis V; Panagiototglou T; Arvanitaki V; Fragiskou S; Eleftheriadou M; Tsika C; Papadaki T Semin Ophthalmol; 2009; 24(6):225-30. PubMed ID: 19954371 [TBL] [Abstract][Full Text] [Related]
59. The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. Mehta H; Fraser-Bell S; Nguyen V; Lim LL; Gillies MC Ophthalmol Retina; 2018 Mar; 2(3):231-234. PubMed ID: 31047591 [TBL] [Abstract][Full Text] [Related]
60. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]